BCL2 and acute myeloid leukemia: Recurrent AML frequently develops resistance to first-line agents (9), and responses to alternative targeted therapies including decitabine (a DNA-hypomethylating agent) or venetoclax (a Bcl-2 inhibitor) are often modest and short lived (10, 11), highlighting the need for novel therapeutic strategies.